Study S000351

A Dose Block-randomized, Double-blind, Placebo-controlled, Dose-escalating, Phase I Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of DA-3091 After Subcutaneous Injection in Healthy Male Subjects

ClinicalTrials.gov record

Registration

Registration: NCT01156779
Acronym: SR-Exenatide
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 31
Start: 2010-07
Primary completion: 2012-04
Lead sponsor: Dong-A Pharmaceutical Co., Ltd.
Conditions: Diabetes Mellitus
Interventions: DRUG:SR-exenatide
Results posted: FALSE

Registered primary outcomes

Assessment of safety [84 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.